Shares of Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) were down 10.1% during trading on Monday . The company traded as low as C$11.01 and last traded at C$11.01. Approximately 2,900 shares traded hands during trading, an increase of 146% from the average daily volume of 1,180 shares. The stock had previously closed at C$12.25.
Neuren Pharmaceuticals Trading Down 10.1%
The stock’s 50-day simple moving average is C$12.73 and its 200 day simple moving average is C$11.16.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
Further Reading
- Five stocks we like better than Neuren Pharmaceuticals
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity
- Want to Profit on the Downtrend? Downtrends, Explained.
- Congress Beat the Market Again—Here Are the 3 Stocks They Bought
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Go on a Shopping Spree With 3 Top Retail ETFs
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
